Impact Therapeutics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biotech developing targeted cancer therapies, with a late-stage PARP inhibitor and novel DDR assets in its pipeline.
Oncology
Technology Platform
A drug discovery platform focused on DNA damage response (DDR) pathways to develop novel small molecule oncology therapeutics.
Opportunities
Potential to capture market share in China's oncology market with its late-stage PARP inhibitor and first-mover advantage on novel DDR targets.
Risk Factors
Heavy reliance on the success of its lead PARP inhibitor candidate in a market with several approved alternatives.
Competitive Landscape
Competes in the crowded PARP inhibitor market and must demonstrate superiority or niche advantages for its lead candidate.